Clinical Trial Update: SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating SPEL as introductory treatment following immunochemotherapy for relapsed/refractory diffuse large B-cell lymphoma with p53 and/or c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• SPEL

Snippet

Sponsor: The Affiliated Hospital of Qingdao University | Conditions: DLBCL | Phase 1, Phase 2 | Status: UNKNOWN